Bioinformatics and Biostatistics Core

摘要（生物信息学和生物统计学核心） 随着大规模、高维分子信息和临床研究数据的日益可用， 以及分析这些复杂数据的先进统计方法，提供了前所未有的 促进心脏代谢疾病的临床和转化研究的机会。然而，广泛 需要研究设计、生物信息学、生物统计学和计算专业知识， 这些前沿的生物医学研究进展。作为拟议的生物医学中心的一部分 卓越研究（COBRE）第2阶段赠款，我们将建立一个新的生物信息学和生物统计学 核心（BBC），将作为研究设计，生物信息学，生物统计学和计算支持的中心。 英国广播公司的总体目标是：1。为了扩展研究设计、生物信息学、生物统计学和 计算资源，能力，并通过建立一个支持COBRE计划， 专用的分析和计算基础设施;以及2.）培训和协助研究项目负责人 （RPL），试点项目负责人（PPL），其他COBRE研究人员和合作者在应用 先进的生物信息学和生物统计学方法，促进高质量的研究。实现这些 英国广播公司将为RPL、PPL、其他COBRE调查人员和合作者提供支持， 研究设计，生物信息学和生物统计学，需要进行高质量的临床和转化 心脏代谢疾病研究（目标1）。此外，我们将利用我们在生物信息学方面的专业知识， 生物统计学开发和实施新的工具和方法，为RPL的研究项目量身定制， PPL、其他COBRE研究人员和合作者，并可能被杜兰科学研究所改编和采用。 社区作为目标2的一部分，英国广播公司将为RPL，PPL，其他COBRE提供培训机会， 研究人员和合作者寻求扩大和提高他们的临床和转化研究技能。 我们建议的研讨会和一对一的导师机会将建立生物信息学，生物统计学， 计算研究技能，使COBRE调查人员和合作者能够独立进行 心脏代谢疾病的严谨临床和转化研究。为了确保持续的可见性， 在COBRE资助期结束后，我们还将建立一个自我维持的BBC， 作为杜兰大学科学界的长期资源（目标3）。我们自我维持的核心 该设施将得到NIH资助的研究以及非COBRE的收费服务的支持 investigators.总的来说，BBC是COBRE第二阶段计划的关键组成部分，该计划将 广泛用于所有四个拟议的COBRE研究和试点项目。英国广播公司将提供杜兰 研究人员提供必要的支持，以加速科学发现，并将这些发现转化为 公共卫生实践和心脏代谢疾病的临床护理。

ABSTRACT (Bioinformatics and Biostatistics Core) The growing availability of large-scale, high-dimensional molecular information and clinical research data, as well as sophisticated statistical methodologies for analyzing these complex data, provides unprecedented opportunity to advance clinical and translational research of cardiometabolic disease. However, extensive study design, bioinformatics, biostatistics, and computational expertise is needed to appropriately incorporate these cutting-edge advancements into biomedical research. As part of the proposed Centers for Biomedical Research Excellence (COBRE) Phase 2 grant, we will establish a new Bioinformatics and Biostatistics Core (BBC) that will serve as a hub for study design, bioinformatics, biostatistics, and computational support. The overall objectives of the BBC are: 1.) To expand study design, bioinformatics, biostatistics, and computational resources, capacity, and support in the COBRE program through the establishment of a dedicated analytic and computational infrastructure; and 2.) To train and assist research project leaders (RPLs), pilot project leaders (PPLs), other COBRE investigators, and collaborators in the application of sophisticated bioinformatics and biostatistics approaches that promote high-quality research. To achieve these objectives, the BBC will provide RPLs, PPLs, other COBRE investigators, and collaborators with the support in study design, bioinformatics, and biostatistics that is needed to conduct high-quality clinical and translational research of cardiometabolic disease (Aim 1). Furthermore, we will leverage our expertise in bioinformatics and biostatistics to develop and implement novel tools and methods that are tailored to Research Projects of RPLs, PPLs, other COBRE investigators, and collaborators and may be adapted and adopted by the Tulane scientific community. As part of Aim 2, the BBC will provide training opportunities to RPLs, PPLs, other COBRE investigators, and collaborators seeking to broaden and enhance their clinical and translational research skills. Our proposed workshops and one-on-one mentorship opportunities will build bioinformatics, biostatistics, and computational research skills, empowering COBRE investigators and collaborators to independently conduct rigorous clinical and translational research in cardiometabolic disease. To ensure continued visibility and utilization of the BBC beyond the COBRE funding period, we will also establish a self-sustaining BBC that will serve as a long-term resource for the Tulane University scientific community (Aim 3). Our self-sustaining core facility will be supported by NIH-funded research studies, as well as fee-based services for non-COBRE investigators. In total, the BBC is a critical component of the COBRE Phase 2 program, which will be extensively utilized by all four proposed COBRE Research and Pilot Projects. The BBC will provide Tulane investigators with the supports necessary to accelerate scientific discovery and translate those discoveries to public health practice and clinical care in cardiometabolic disease.